Author + information
- Sho Torii1,
- Frank Kolodgie1,
- Qi Cheng1,
- Eduardo Acampado1,
- Laura Perkins2,
- Syed Hossainy2,
- Stephen Pacetti3,
- Aloke Finn4 and
- Renu Virmani1
- 1CVPath Institute, Inc., Gaithersburg, Maryland, United States
- 2Abbott Vascular, Santa Clara, California, United States
- 3University california, Berkeley / University of Houston, Santa Clara, California, United States
- 4CVPath Institute Inc. and University of Maryland, Baltimore, Gaithersburg, Maryland, United States
Clinical data indicate differences in acute thrombosis among different drug-eluting stents (DES), which may relate to properties of DES polymer coatings and stent design. We sought to investigate stent thrombogenicity between a durable fluoropolymer coated DES (Xience Alpine, X-EES, Abbott Vascular), a durable BioLinx polymer coated DES (Resolute Onyx, R-ZES, Medtronic) and a Multi-Link Vision control (BMS) in a preclinical model.
X-EES (n=7), R-ZES (n=8), and BMS (n=3) were assessed in an established ex vivo carotid to jugular arteriovenous porcine shunt model (Otsuka F et al, JACC Cardiovasc Interven 8: 1248-1260, 2015). Following the shunt, stents were bisected and each half was dual immunostained using platelet cocktail (CD61/CD42b) and inflammatory marker for neutrophils (PM1) or monocytes (CD14). Antibody staining was visualized by confocal microscopy and quantified by histomorphometry.
X-EES showed a significantly lower percentage of adherent platelets on struts as compared to R-ZES and BMS (2.0 % vs. 9.1 % vs. 37.8 %, respectively, p=0.003) (Figure). Moreover, inflammatory cell density (positive cells/mm2) was lowest for X-EES as compared with R-ZES and BMS for both neutrophils (40.4 ± 16.5 vs. 471.6 ± 211.7 vs. 768.7 ± 458.6, P= 0.0005) and monocytes (33.4 ± 18.6 vs. 287.4 ± 96.1 vs. 399.4 ± 212.9, P= 0.0001).
Durable fluoropolymer X-EES exhibits less platelet and inflammatory cell adherence as compared with R-ZES and BMS in the porcine shunt model. This result may reflect a more favorable safety profile in the clinical setting.
CORONARY: Stents: Drug-Eluting